Get the Stockscreener App
187.86
2.87%
5.24
Krystal Biotech Inc stock is traded at $187.86, with a volume of 291.52K.
It is up +2.87% in the last 24 hours and up +23.96% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$182.62
Open:
$184.99
24h Volume:
291.52K
Relative Volume:
1.13
Market Cap:
$5.41B
Revenue:
$241.52M
Net Income/Loss:
$52.37M
P/E Ratio:
105.54
EPS:
1.78
Net Cash Flow:
$58.06M
1W Performance:
+22.59%
1M Performance:
+23.96%
6M Performance:
-6.83%
1Y Performance:
+73.93%
1-Day Range:
$184.12
$189.19
1-Week Range:
$148.00
$190.00
52-Week Range:
$107.50
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
187.86 | 5.41B | 241.52M | 52.37M | 58.06M | 1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
William Blair Comments on Krystal Biotech Q1 Earnings - Defense World
Krystal Biotech projects EU and Japan launches for VYJUVEK in 2025, targeting $1B global peak sales - MSN
Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know - MSN
Krystal Biotech (NASDAQ:KRYS) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Chardan Capital Forecasts Strong Price Appreciation for Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus (KRYS) - Seeking Alpha
Krystal Biotech (NASDAQ:KRYS) Trading 7.1% Higher on Analyst Upgrade - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Holdings Cut by Allspring Global Investments Holdings LLC - Defense World
Vontobel Holding Ltd. Decreases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up - MSN
Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Declines By 7.4% - MarketBeat
Krystal Biotech Earnings Call: Optimism Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Krystal stock, $221 target By Investing.com - Investing.com South Africa
A Glimpse Into The Expert Outlook On Krystal Biotech Through 9 Analysts - Benzinga
Krystal Biotech (NASDAQ:KRYS) Given "Buy" Rating at HC Wainwright - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Shares Gap DownWhat's Next? - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Posts Quarterly Earnings Results, Beats Estimates By $0.23 EPS - MarketBeat
H.C. Wainwright maintains Buy on Krystal stock, $221 target - Investing.com
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2024 Earnings Call Transcript - Insider Monkey
3 US Growth Companies With High Insider Ownership Expecting Up To 68% Earnings Growth - Simply Wall St
TimesSquare Capital Management LLC Purchases 44,646 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech’s (KRYS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Krystal Biotech (KRYS) Expected to Announce Earnings on Wednesday - MarketBeat
Krystal Biotech Inc (KRYS) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Krystal Biotech Reports Robust 2024 Financial Growth - TipRanks
Krystal Biotech shares rise 20% following earnings call - The Business Journals
Krystal Biotech earnings beat by $0.31, revenue fell short of estimates - Investing.com Canada
High Growth Tech Stocks in United States to Watch - Simply Wall St
Earnings call transcript: Krystal Biotech Q4 2024 beats EPS forecasts By Investing.com - Investing.com Nigeria
Earnings call transcript: Krystal Biotech Q4 2024 beats EPS forecasts - Investing.com
Krystal Biotech rises after quarterly revenue beat - TradingView
Krystal Biotech Inc (KRYS) Q4 2024 Earnings Report Preview: What to Look For - GuruFocus.com
Krystal Biotech Q4 Net Income, Revenue Rise -February 19, 2025 at 07:41 am EST - Marketscreener.com
Krystal Biotech, Inc. SEC 10-K Report - TradingView
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results - The Manila Times
Krystal Biotech reports Q4 EPS $1.52, consensus $1.85 - TipRanks
Krystal Biotech Reports 116% Revenue Increase in Q4 2024 and 473% Growth for Full Year, Secures Full Sanctioning for KB407 Phase 1 Protocol - Nasdaq
Earnings Flash (KRYS) Krystal Biotech Posts Q4 Adjusted EPS $1.52, vs. FactSet Est of $1.20 - Marketscreener.com
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire Inc.
Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 7.4% in January - Defense World
Entropy Technologies LP Buys New Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Decreased by Mirae Asset Global Investments Co. Ltd. - Defense World
Yousif Capital Management LLC Lowers Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
abrdn plc Buys 13,979 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Looking Into Krystal Biotech's Recent Short Interest - Benzinga
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Lowered by Jennison Associates LLC - MarketBeat
KBC Group NV Purchases 297 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):